Suppr超能文献

相似文献

1
Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12956-60. doi: 10.1073/pnas.95.22.12956.
2
Discovering transthyretin amyloid fibril inhibitors by limited screening.
Bioorg Med Chem. 1998 Aug;6(8):1389-401. doi: 10.1016/s0968-0896(98)00130-8.
3
Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
Biochemistry. 1995 Oct 17;34(41):13527-36. doi: 10.1021/bi00041a032.
4
Inhibiting transthyretin amyloid fibril formation via protein stabilization.
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15051-6. doi: 10.1073/pnas.93.26.15051.
9
An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
Biochemistry. 2001 Sep 25;40(38):11442-52. doi: 10.1021/bi011194d.

引用本文的文献

1
Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic Benefits.
Cardiol Ther. 2025 Sep;14(3):333-350. doi: 10.1007/s40119-025-00423-7. Epub 2025 Jul 29.
2
Quercetin: Molecular Insights into Its Biological Roles.
Biomolecules. 2025 Feb 20;15(3):313. doi: 10.3390/biom15030313.
3
A bitter anti-inflammatory drug binds at two distinct sites of a human bitter taste GPCR.
Nat Commun. 2024 Nov 18;15(1):9991. doi: 10.1038/s41467-024-54157-6.
4
Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis.
Pharmaceuticals (Basel). 2024 Sep 17;17(9):1225. doi: 10.3390/ph17091225.
5
Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment.
Curr Heart Fail Rep. 2024 Aug;21(4):305-321. doi: 10.1007/s11897-024-00669-7. Epub 2024 May 29.
7
Drug Repurposing: Insights into Current Advances and Future Applications.
Curr Med Chem. 2025;32(3):468-510. doi: 10.2174/0109298673266470231023110841.
8
Transthyretin Binding Mode Dichotomy of Fluorescent -Stilbene Ligands.
ACS Chem Neurosci. 2023 Mar 1;14(5):820-828. doi: 10.1021/acschemneuro.2c00700. Epub 2023 Feb 13.
10
Multidisciplinary Approaches for Transthyretin Amyloidosis.
Cardiol Ther. 2021 Dec;10(2):289-311. doi: 10.1007/s40119-021-00222-w. Epub 2021 Jun 4.

本文引用的文献

1
Crystallographic R factor refinement by molecular dynamics.
Science. 1987 Jan 23;235(4787):458-60. doi: 10.1126/science.235.4787.458.
2
Discovering transthyretin amyloid fibril inhibitors by limited screening.
Bioorg Med Chem. 1998 Aug;6(8):1389-401. doi: 10.1016/s0968-0896(98)00130-8.
3
The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways.
Curr Opin Struct Biol. 1998 Feb;8(1):101-6. doi: 10.1016/s0959-440x(98)80016-x.
8
Alzheimer's disease: genotypes, phenotypes, and treatments.
Science. 1997 Jan 31;275(5300):630-1. doi: 10.1126/science.275.5300.630.
9
Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.
N Engl J Med. 1997 Feb 13;336(7):466-73. doi: 10.1056/NEJM199702133360703.
10
Inhibiting transthyretin amyloid fibril formation via protein stabilization.
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15051-6. doi: 10.1073/pnas.93.26.15051.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验